



**Initial Disclosure Notice**

**Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date on which issuer listed or appointment made:

Fisher & Paykel Healthcare Corporation Limited
3 April 2024
1 April 2024

**Director or senior manager giving disclosure**

Full name:
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Andrew Grant Niccol
Fisher & Paykel Healthcare Corporation Limited
Chief Operating Officer

**Summary of relevant interest (excluding specified derivatives)**

Class of quoted financial product:
Number held in class:
Nature of relevant interest:
Current registered holder:

(a) Ordinary Shares (b) Options to acquire Ordinary Shares (c) Performance Share Rights
(a) 1501 Ordinary Shares, including a beneficial interest in 131 shares issued to a trustee under an Employee Share Purchase Scheme (b) 25,066 Options (c) 12,146 Performance Share Rights
Beneficial
Andrew Grant Niccol

**Summary of specified derivatives relevant interest (if applicable)**

Type of derivative:
Class of underlying financial products:


<b>Details of derivative</b>
The notional value of the derivative (if any) or the notional amount of underlying products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative(if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:


For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

Raelene Leonard
3 April 2024
Raelene Leonard, Company Secretary



## Initial Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date on which issuer listed or appointment made:

Fisher & Paykel Healthcare Corporation Limited
3 April 2024
1 April 2024

#### Director or senior manager giving disclosure

Full name:
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Justin Peter Callahan
Fisher & Paykel Healthcare Corporation Limited
Vice President - Sales & Marketing

#### Summary of relevant interest (excluding specified derivatives)

Class of quoted financial product:
Number held in class:
Nature of relevant interest:
Current registered holder:

(a) Ordinary Shares
(b) Options to acquire Ordinary Shares
(c) Performance Share Rights
(a) 177,161 Ordinary Shares
(b) 98,992 Options
(c) 47,948 Performance Share Rights
Beneficial
Justin Peter Callahan

#### Summary of specified derivatives relevant interest (if applicable)

Type of derivative:
Class of underlying financial products:


#### Details of derivative

The notional value of the derivative (if any) or the notional amount of underlying products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative(if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:


For that derivative, -

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


#### Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

Raelene Leonard
3 April 2024
Raelene Leonard, Company Secretary